NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Bill Bonello, President - Informatics Division, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Stephens Annual Investment Conference 2021 held in Nashville, Tennessee on Friday, December 3, 2021 at 9:00am CT. The presentation will be webcast live and accessible online via the investors section of the Company's website, www.neogenomics.com.

NeoGenomics To Participate In The Stephens Annual Investment Conference 2021

FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has appointed Dave Daly to serve on its Board of Directors. Dave Daly joined our Board of Directors effective November 10, 2021.

NeoGenomics Appoints Dave Daly to Its Board of Directors

NeoGenomics, Inc.'s (NEO) CEO Mark Mallon on Q3 2021 Results - Earnings Call Transcript

NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -1.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q3 Loss, Lags Revenue Estimates

NeoGenomics (NASDAQ:NEO) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: NeoGenomics Q3 Earnings

Third-Quarter 2021 Results and Highlights: Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million Consolidated revenue decreased 3% due to the discontinuation of prior year COVID-19 revenue; consolidated revenue increased 12% when excluding prior year COVID-19 revenue Announces plan to double its Clinical Services sales and medical affairs teams to further support RaDaR™ and drive the next phase of the Company's growth FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company "), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its third-quarter results for the period ended September 30, 2021.

NeoGenomics Reports Revenue of $121 Million in the Third Quarter

FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today an upcoming leadership team transition. William Bonello will be named Chief Financial Officer as of January 1, 2022.

NeoGenomics Announces Leadership Team Transition

Inivata Announces Clinical Collaboration with Princess Margaret Cancer Cente r for the us e of its Liquid Biopsy Assay s

Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays

Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has entered into a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata's liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.

NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays

FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2021, financial results on Thursday, November 4, 2021. The Company has scheduled a webcast and conference call to discuss their third quarter results on Thursday, November 4, 2021 at 8:30 AM EDT.

NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021

Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT.

NeoGenomics Announces Board of Directors' Transition

Guardant Health Inc

Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people familiar with the matter. Related:   Guardant Health Weighing NeoGenomics Acquisition: Bloomberg.

Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg

Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar with the matter.  Related:   Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates.

Guardant Health Weighing NeoGenomics Acquisition: Bloomberg

FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") alongside collaborators, will present new data on its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst®-Lung liquid biopsy test at the European Society for Medical Oncology (ESMO) Congress, taking place on 16-21 September 2021. Inivata will present two posters highlighting data for RaDaR as a highly sensitive, personalized assay for the detection of residual disease and recurrence in head and neck squamous cell carcinoma (HNSCC) and new data in early-stage breast cancer.

NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021

FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Morgan Stanley 19th Annual Global Healthcare Conference, on Tuesday, September 14, 2021 at 10:15am ET. The presentation will be webcast live and accessible online via the investors section of the Company's website, www.neogenomics.com.

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

NeoGenomics, Inc. (NEO) CEO Mark Mallon on Q2 2021 Results - Earnings Call Transcript

Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.06).

Recap: NeoGenomics Q2 Earnings

Second-Quarter 2021 Results and Highlights: Consolidated revenue increased 40% to $122 million Clinical Services revenue increased 37% to $101 million Pharma Services revenue increased 55% to $20 million Completed the acquisitions of Trapelo Health in April and Inivata Limited in June FORT MYERS, FL / ACCESSWIRE / August 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2021. "Second-quarter results were strong as all three of our divisions grew significantly year-over-year.

NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline

Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff

Bear of the Day: NeoGenomics (NEO)

FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its second quarter 2021, financial results on Friday, August 6, 2021. The Company has scheduled a webcast and conference call to discuss their first quarter results on Friday, August 6, 2021 at 8:30 AM EDT.

NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021

NEO operates a broad network of cancer-focused testing centers in the U.S., Europe, and Asia, and is actively seeking new markets to enter. Although the COVID pandemic had an adverse effect on the company's financials, all of the laboratories and testing services remained opened/uninterrupted.

NeoGenomics: Strong Growth Potential For A Leader In Cancer Diagnostic Testing

Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has completed its acquisition of Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England.

NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform

NeoGenomics (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: NeoGenomics (NEO)

Howard Hughes

HealthEquity

StoneCo

Spotting bloated toxic stocks on a regular basis and abandoning them at the right time is one of the secrets to a winning investment strategy.

News for NeoGenomics Stock (NEO)